Sfoglia per Autore
The relationship between nevirapine plasma concentrations and abnormal liver function tests
2004-01-01 ALMOND LM; BOFFITO M; HOGGARD PG; BONORA S; RAITERI R; REYNOLDS HE; GARAZZINO S; SINICCO A; KHOO SH; BACK DJ; DI PERRI G
Impact of nevirapine (NVP) trough concentrations (Ctrough) on time to achieve and time maintenance of viral suppression (VS) in HIV+ patients taking NVP-based regimens
2004-01-01 Bonora S.; Requena D.; Garazzino S.; Sciandra M.; D'Avolio A.; Raiteri R.; Canta F.; Marrone R.; Boffito M.; Caci A.; Sinicco A.; Di Perri G.
Osteomyelitis caused by Enterobacter cancerogenus infection following a traumatic injury: case report and review of the literature
2005-01-01 S. GARAZZINO; A. APRATO; A. MAIELLO; A. MASSE'; A. BIASIBETTI; F.G. DE ROSA; G. DI PERRI
Treatment of acute C hepatitis in HIV-infected patients
2005-01-01 AUDAGNOTTO S; DE ROSA FG; BARGIACCHI O; GARAZZINO S; VERONESE L; CARITI G; DI PERRI G
[Ertapenem. A new carbapenem in a single dose for community acquired infection]
2005-01-01 DI PERRI G; BARGIACCHI O; GARAZZINO S; AUDAGNOTTO S; DE ROSA FG
Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting
2005-01-01 GONZÁLEZ DE REQUENA D; BONORA S; GARAZZINO S; SCIANDRA M; D'AVOLIO A; RAITERI R; MARRONE R; BOFFITO M; DE ROSA FG; SINICCO A; DI PERRI G
Continuous infusion of amphotericin B deoxycholate: does decreased nephrotoxicity couple with time-dependent pharmacodynamics?
2006-01-01 DE ROSA FG; BARGIACCHI O; AUDAGNOTTO S; GARAZZINO S; RANIERI VM; DI PERRI G
Treatment of acute C hepatitis in intravenous drug users
2006-01-01 BARGIACCHI O; AUDAGNOTTO S; GARAZZINO S; DE ROSA F
Resolution of HCV infection after highly active antiretroviral therapy in a HIV-HCV coinfected patient
2006-01-01 DE ROSA FG; AUDAGNOTTO S; BARGIACCHI O; GARAZZINO S; AGUILAR MARUCCO D; VERONESE L; CANTA F; BONORA S; SINICCO A; DI PERRI G
Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three cases
2006-01-01 GARAZZINO S; TETTONI M; CALCAGNO A; D'AVOLIO A; BONORA S; DI PERRI G
Tipranavir (TPV) genotypic Inhibitory Quotient (gIQ) predicts virological responce at 24 weeks to TPV-based salvage regimens.
2006-01-01 Bonora S; Gonzalez de Requena D; Calcagno A; Milia MG; D’Avolio A; Sciandra M; Garazzino S; Siccardi M; Sinicco A; Di Perri G.
Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C
2006-01-01 F. DE ROSA; O. BARGIACCHI; S. AUDAGNOTTO; S. GARAZZINO; G. CARITI; R. RAITERI; G. DI PERRI
The early HCV RNA dynamics in patients with acute hepatitis C treated with pegylated interferon-alpha2b
2006-01-01 DE ROSA FG; BARGIACCHI O; AUDAGNOTTO S; GARAZZINO S; CARITI G; VERONESE L; RAITERI R; CALLERI G; DI PERRI G
Antibiotic diffusion in pseudoarthrosic infected bone: glycopeptides, fluoroquinolones and carbapenems
2007-01-01 S. Garazzino; A. Aprato; D. Aloj; F.G. De Rosa; A. D'Avolio; A. Massé; G. Di Perri
Clinical significance of pharmacokinetics of ertapenem in an outpatient setting
2007-01-01 Garazzino S.; De Rosa F. G.; D'Avolio A.; Michelazzo M.; Di Perri G.
Haematological safety of long-term therapy with linezolid
2007-01-01 GARAZZINO S; DE ROSA FG; BARGIACCHI O; AUDAGNOTTO S; MAIELLO A; DI PERRI G
Twelve-week treatment of acute hepatitis C virus with pegylated interferon- alpha -2b in injection drug users
2007-01-01 DE ROSA F; BARGIACCHI O; AUDAGNOTTO S; GARAZZINO S; CARITI G; CALLERI G; LESIOBA O; BELLORO S; RAITERI R; DI PERRI G
[Invasive aspergillosis in an immunocompromised patient: clinical and therapeutic considerations]
2007-01-01 DE ROSA FG; GARAZZINO S; AUDAGNOTTO S; MICHELAZZO M; GOBBI F
Post-traumatic osteomyelitis due to Aspergillus flavus successfully treated with voriconazole: a case report
2008-01-01 Garazzino S; Maiello A; DE Rosa FG; Aprato A; Di Perri G.
Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens
2008-01-01 Daniel Gonzalez de; Stefano Bonora; Andrea Calcagno; Antonio D'Avolio; Marco Siccardi; Silvia Fontana; Maria Grazia Milia; Mauro Sciandra; Silvia Garazzino; Antonio Di Garbo; Lorena Baietto; Laura Trentini; Giovanni Di Perri
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
The relationship between nevirapine plasma concentrations and abnormal liver function tests | 2004 | ALMOND LM; BOFFITO M; HOGGARD PG; BONORA S; RAITERI R; REYNOLDS HE; GARAZZINO S; SINICCO A; KHOO SH; BACK DJ; DI PERRI G | |
Impact of nevirapine (NVP) trough concentrations (Ctrough) on time to achieve and time maintenance of viral suppression (VS) in HIV+ patients taking NVP-based regimens | 2004 | Bonora S.; Requena D.; Garazzino S.; Sciandra M.; D'Avolio A.; Raiteri R.; Canta F.; Marrone R.; Boffito M.; Caci A.; Sinicco A.; Di Perri G. | |
Osteomyelitis caused by Enterobacter cancerogenus infection following a traumatic injury: case report and review of the literature | 2005 | S. GARAZZINO; A. APRATO; A. MAIELLO; A. MASSE'; A. BIASIBETTI; F.G. DE ROSA; G. DI PERRI | |
Treatment of acute C hepatitis in HIV-infected patients | 2005 | AUDAGNOTTO S; DE ROSA FG; BARGIACCHI O; GARAZZINO S; VERONESE L; CARITI G; DI PERRI G | |
[Ertapenem. A new carbapenem in a single dose for community acquired infection] | 2005 | DI PERRI G; BARGIACCHI O; GARAZZINO S; AUDAGNOTTO S; DE ROSA FG | |
Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting | 2005 | GONZÁLEZ DE REQUENA D; BONORA S; GARAZZINO S; SCIANDRA M; D'AVOLIO A; RAITERI R; MARRONE R; BOFFITO M; DE ROSA FG; SINICCO A; DI PERRI G | |
Continuous infusion of amphotericin B deoxycholate: does decreased nephrotoxicity couple with time-dependent pharmacodynamics? | 2006 | DE ROSA FG; BARGIACCHI O; AUDAGNOTTO S; GARAZZINO S; RANIERI VM; DI PERRI G | |
Treatment of acute C hepatitis in intravenous drug users | 2006 | BARGIACCHI O; AUDAGNOTTO S; GARAZZINO S; DE ROSA F | |
Resolution of HCV infection after highly active antiretroviral therapy in a HIV-HCV coinfected patient | 2006 | DE ROSA FG; AUDAGNOTTO S; BARGIACCHI O; GARAZZINO S; AGUILAR MARUCCO D; VERONESE L; CANTA F; BONORA S; SINICCO A; DI PERRI G | |
Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three cases | 2006 | GARAZZINO S; TETTONI M; CALCAGNO A; D'AVOLIO A; BONORA S; DI PERRI G | |
Tipranavir (TPV) genotypic Inhibitory Quotient (gIQ) predicts virological responce at 24 weeks to TPV-based salvage regimens. | 2006 | Bonora S; Gonzalez de Requena D; Calcagno A; Milia MG; D’Avolio A; Sciandra M; Garazzino S; Siccardi M; Sinicco A; Di Perri G. | |
Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C | 2006 | F. DE ROSA; O. BARGIACCHI; S. AUDAGNOTTO; S. GARAZZINO; G. CARITI; R. RAITERI; G. DI PERRI | |
The early HCV RNA dynamics in patients with acute hepatitis C treated with pegylated interferon-alpha2b | 2006 | DE ROSA FG; BARGIACCHI O; AUDAGNOTTO S; GARAZZINO S; CARITI G; VERONESE L; RAITERI R; CALLERI G; DI PERRI G | |
Antibiotic diffusion in pseudoarthrosic infected bone: glycopeptides, fluoroquinolones and carbapenems | 2007 | S. Garazzino; A. Aprato; D. Aloj; F.G. De Rosa; A. D'Avolio; A. Massé; G. Di Perri | |
Clinical significance of pharmacokinetics of ertapenem in an outpatient setting | 2007 | Garazzino S.; De Rosa F. G.; D'Avolio A.; Michelazzo M.; Di Perri G. | |
Haematological safety of long-term therapy with linezolid | 2007 | GARAZZINO S; DE ROSA FG; BARGIACCHI O; AUDAGNOTTO S; MAIELLO A; DI PERRI G | |
Twelve-week treatment of acute hepatitis C virus with pegylated interferon- alpha -2b in injection drug users | 2007 | DE ROSA F; BARGIACCHI O; AUDAGNOTTO S; GARAZZINO S; CARITI G; CALLERI G; LESIOBA O; BELLORO S; RAITERI R; DI PERRI G | |
[Invasive aspergillosis in an immunocompromised patient: clinical and therapeutic considerations] | 2007 | DE ROSA FG; GARAZZINO S; AUDAGNOTTO S; MICHELAZZO M; GOBBI F | |
Post-traumatic osteomyelitis due to Aspergillus flavus successfully treated with voriconazole: a case report | 2008 | Garazzino S; Maiello A; DE Rosa FG; Aprato A; Di Perri G. | |
Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens | 2008 | Daniel Gonzalez de; Stefano Bonora; Andrea Calcagno; Antonio D'Avolio; Marco Siccardi; Silvia Fontana; Maria Grazia Milia; Mauro Sciandra; Silvia Garazzino; Antonio Di Garbo; Lorena Baietto; Laura Trentini; Giovanni Di Perri |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile